Related Experiment Video
Updated: Jul 7, 2025
08:38
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
16.9K
Current Immunosuppressive Treatment for Takayasu Arteritis.
Yoh Arita1,2, Tomohiko Ishibashi2, Yoshikazu Nakaoka2,3
1Department of Cardiology, Japan Community Healthcare Organization Osaka Hospital.
Summary
Takayasu arteritis (TAK) treatment is evolving with biological disease-modifying anti-rheumatic drugs (bDMARDs) like tocilizumab (TCZ). This review covers their use and guidelines for managing TAK patients undergoing procedures.
Area of Science:
- Rheumatology
- Cardiology
- Immunology
Background:
- Takayasu arteritis (TAK) is a rare large vessel vasculitis causing stenosis, occlusion, and aneurysms.
- Glucocorticoids are traditional treatments, but biological agents are emerging.
- Tocilizumab (TCZ) and other bDMARDs are changing the therapeutic landscape for TAK.
Purpose of the Study:
- To review the evidence for tocilizumab (TCZ) and other immunosuppressants in Takayasu arteritis (TAK).
- To provide an update on the current status and guidelines for bDMARDs in TAK management.
- To inform cardiologists and surgeons about managing patients on these novel therapies.
Main Methods:
- Literature review of clinical studies on bDMARDs in Takayasu arteritis (TAK).
- Analysis of current treatment guidelines and expert recommendations.
- Discussion of the implications for invasive procedures and surgery in TAK patients.
Main Results:
- Several bDMARDs, including TCZ, show promise in treating TAK.
- The use of bDMARDs in TAK is increasing.
- Janus kinase inhibitors may also offer therapeutic benefits.
Conclusions:
- bDMARDs represent a significant advancement in Takayasu arteritis (TAK) treatment.
- Guidelines are evolving to incorporate these novel therapies.
- Careful consideration is needed for patients on bDMARDs requiring invasive interventions.
Keywords:
Biological disease-modifying anti-rheumatic drugsJanus kinase inhibitorsTakayasu arteritisTocilizumabMore Related Videos
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
141
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
141
01:29Drugs for Treatment of Ulcerative Colitis in IBD
145
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
145
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
121
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
121
01:27Tumor Immunotherapy
529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
01:29Inflammatory Bowel Disease IV: Pharmacological Management
128
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
128